Serina Therapeutics Inc (SER)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $37.73M
Last updated: Nov 17, 2026 at 4:10 PM ET
Serina Therapeutics Inc (SER) Statistics
Serina Therapeutics (SER) has a market cap of $37.73M and an enterprise value of $21.50M. It kept -19596.80% of revenue as net income over the last 12 months. Its share count is up 145.80% from a year earlier.
Total Valuation
Enterprise value is 43.02% below the market cap, as cash exceeds debt.
| Market Cap | $37.73M |
|---|---|
| Enterprise Value | $21.50M |
| Latest price (Nov 17, 2026) | $1.36 |
Key Dates
The next earnings report is expected on May 10, 2027, covering the quarter ending Mar 31, 2027.
| Next Earnings Date | May 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 277.5x and 2.5x. Its year-end P/S ranged from 147.2x to 621.5x from 2019 to 2025.
| P/S Ratio | 277.5x |
|---|---|
| P/B Ratio | 2.5x |
Price Statistics
The stock is down 66.63% over 52 weeks and trades 28.04% below its 50-day average.
| Beta (1Y) | 1.27 |
|---|---|
| 52-Week Change | -66.63% |
| 1-Month Change | -17.27% |
| 3-Month Change | -49.82% |
| 6-Month Change | -15.22% |
| 5-Year Change | -93.29% |
| Total Return (1Y) | -66.63% |
| Total Return (3Y CAGR) | -55.37% |
| Total Return (5Y CAGR) | -45.13% |
| Return vs SPY (1Y) | -75.26% |
| Max Drawdown (1Y) | -69.95% |
| Max Drawdown (3Y) | -94.27% |
| Sharpe Ratio (1Y) | -0.83 |
| Correlation with SPY (1Y) | 0.14 |
| 50-Day Average | $1.89 |
| 200-Day Average | $2.01 |
| 52-Week Range | $1.14 to $4.26 |
| RSI (14 Days) | 34.0 |
| Average Volume (20 Days) | 73.01K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.62x current liabilities, and total debt is 0.23x shareholder equity.
| Current Ratio | 4.62x |
|---|---|
| Quick Ratio | 4.62x |
| Debt / Equity | 0.23x |
| Interest Coverage | 10.44x |
Returns and Efficiency
Return on invested capital is -109.44% and return on equity is -175.99% over the last 12 months.
| Return on Equity (ROE) | -175.99% |
|---|---|
| Return on Assets (ROA) | -111.99% |
| Return on Invested Capital (ROIC) | -109.44% |
| Return on Capital Employed (ROCE) | -136.51% |
| Asset Turnover | 0.01x |
Scores
SER has an Altman Z-Score of -5.47, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -5.47 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $125.00K over the last 12 months is up 7.76% from the 12 months before.
| Revenue | $125.00K |
|---|---|
| Revenue Growth (YoY) | +7.76% |
| Gross Profit | $102.00K |
| Operating Income | -$27.13M |
| Pretax Income | -$24.47M |
| Net Income | -$24.50M |
| EBITDA | -$23.31M |
| EBIT | -$23.68M |
| Reported EPS (TTM) | -$1.70 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 63.65% of the $21.87M in total assets.
| Cash and Equivalents | $19.40M |
|---|---|
| Total Debt | $3.17M |
| Net Cash | $16.23M |
| Net Cash Per Share | $0.64 |
| Working Capital | $16.40M |
| Shareholder Equity | $13.92M |
| Book Value Per Share | $0.55 |
| Total Assets | $21.87M |
| Total Liabilities | $7.95M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $115.00K of capital spending, operating cash flow left -$22.89M of free cash flow.
| Operating Cash Flow | -$22.78M |
|---|---|
| Capital Expenditures | $115.00K |
| Free Cash Flow | -$22.89M |
| FCF Per Share | -$0.90 |
| Depreciation and Amortization | $364.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -21705.60%.
| Gross Margin | 81.60% |
|---|---|
| Operating Margin | -21705.60% |
| Pretax Margin | -19576.80% |
| Net Margin | -19596.80% |
| EBITDA Margin | -18650.40% |
| EBIT Margin | -18941.60% |
| FCF Margin | -18316.00% |
| Gross Margin (5Y Average) | 89.71% |
Growth
Revenue grew 56.37% a year over 3 years.
| Revenue Growth (3Y CAGR) | +56.37% |
|---|---|
| Revenue Growth (5Y CAGR) | -18.48% |
Dividends and Yields
SER does not pay a dividend. Its free cash flow yield is -65.83%.
| FCF Yield | -65.83% |
|---|---|
| Buyback Yield | -96.88% |
| Shareholder Yield | -96.88% |
Stock Splits
The last split was a 1-for-36 reverse split on Mar 15, 2024.
| Last Split Date | Mar 15, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:36 |
Peer Position
Against 5 similar companies, SER has the highest P/S.
P/S RatioPeer median 6.6x
ROICPeer median -91.22%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -49.61%
| P/S Ratio | 277.5x vs 6.6x median |
|---|---|
| ROIC | -109.44% vs -91.22% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +7.76% vs -49.61% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SER
What is SER's market cap?
Serina Therapeutics has a market cap of $37.73M. Its enterprise value, which adds debt and subtracts cash, is $21.50M.
How many shares of SER are outstanding?
Serina Therapeutics has 25.41M shares outstanding. The count is up 145.80% from a year earlier.
Does SER pay a dividend?
No. Serina Therapeutics does not pay a dividend.
How much debt does SER have?
Serina Therapeutics has $3.17M of total debt and $19.40M of cash and equivalents, a net cash position of $16.23M.
SER pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors